Blue Cross Blue Shield of Louisiana implemented the Zero Dollar Copay (ZDC) program on July 1, 2020. This study aims to evaluate whether the ZDC program can reduce total healthcare expenditures.
Blue Cross Blue Shield of Louisiana’s medical and pharmacy claims from January 2019 to December 2021 was used in this study, and the index date was July 1, 2020. We identified 7603 continuously enrolled members with type 2 diabetes, including 3045 ZDC-eligible members as the ZDC group and 4558 Administrative Service Only group members as the control group. The primary outcome measure was monthly total healthcare expenditure, which included monthly medical and pharmacy spending. ZDC program’s effectiveness was evaluated by a 2-way fixed-effect difference-in-difference regression weighted by odds of propensity scores. The study population was further classified into 3 subgroups based on their baseline use of ZDC-eligible antidiabetic medications: pre-ZDC users, pre-ZDC nonusers, and complex users.
The ZDC pharmacy benefit was associated with a significant reduction in total healthcare spending of $−121.76 per member per month (PMPM) (P = .002) and medical spending of $−131.50 PMPM (P .001) in medical spending, whereas pharmacy spending significantly increased by $102.01 PMPM (P = .022). No significant results were observed for pre-ZDC users and pre-ZDC nonusers.
The ZDC program was effective in reducing total healthcare expenditures among ZDC-eligible members with type 2 diabetes in Louisiana.
What is it about? Type 2 diabetes is a common and expensive condition in the United States, affecting millions and placing a heavy financial burden on both the healthcare system and patients. This study focuses on the Zero Dollar Copay program introduced by Blue Cross Blue Shield of Louisiana, which aims to reduce healthcare costs by eliminating copayments for antidiabetic medications. The problem addressed is the high cost of managing diabetes, which is often exacerbated by patients taking their medications inconsistently due to costs. This research fills a gap by providing evidence on the effectiveness of completely removing copayments, rather than just reducing them. The study suggests that eliminating copayments can lead to significant savings in healthcare spending, especially for those with complex medication needs.
How was the research conducted? The study used a methodological approach called difference-in-differences, which helps compare outcomes over time between a group that received the Zero Dollar Copay benefit and a control group that did not. Researchers utilized medical and pharmacy claims data from January 2019 to December 2021, focusing on members with type 2 diabetes. The researchers analyzed monthly healthcare expenditures, comparing those in the Zero Dollar Copay group to the control group. This method was chosen because it allows for a robust analysis of the program's impact by controlling for other factors that might affect healthcare spending.
What were the results? The main finding is that the Zero Dollar Copay program significantly reduced total healthcare spending by $121.76 per member each month, particularly in medical costs. Interestingly, while pharmacy spending increased slightly for complex users, the overall savings in medical costs were much larger. There were no significant cost changes for those who did not use the eligible medications before the program.
Why are the results important? These results highlight that health technology assessment agencies can consider zero-copay programs as cost-effective interventions. The findings suggest that such programs can change clinical practice by improving medication adherence and reducing unnecessary healthcare use. Specifically, patients with complex medication needs benefit the most by saving on overall healthcare costs while managing their condition better. In the long term, this approach could lead to broader adoption of value-based insurance models, potentially transforming how healthcare resources are allocated.
What are the strengths and weaknesses of this study? The study's robust design and use of detailed data are its strengths, showing the clear benefits of copayment elimination. However, it lacks information on long-term effects and specific demographic impacts, such as those based on race or socioeconomic status. Future research could expand on these findings by exploring the effects in different populations and over longer periods, providing a more comprehensive understanding of the program's benefits.
Note: This content was created with assistance from artificial intelligence (AI) and has been reviewed and edited by ISPOR staff. For more information or for inquiries on ISPOR’s AI policy, click here or contact us at info@ispor.org.